Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02924753Phase 1Unknown

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Role: collaborator

NCT03152435Phase 1Unknown

EGFR CART Cells for Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT03146533Phase 1Unknown

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Role: collaborator

NCT03101709Phase 1Unknown

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Role: collaborator

All 4 trials loaded